Evidence map›Paper›PMID 36978104›Full record

ArticleStem cell research & therapy2023

Stem cell sources and characterization in the development of cell-based products for treating retinal disease: An NEI Town Hall report.

Ashley M Fortress, Kiyoharu J Miyagishima, Amberlynn A Reed, Sally Temple, Dennis O Clegg, Budd A Tucker, Timothy A Blenkinsop, George Harb, Thomas N Greenwell, Tenneille E Ludwig and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Personalized Stem Cell-Based Regeneration in Spinal Cord Injury Care.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Ashley M FortressNational Eye Institute, National Institutes of Health, Bethesda, MD, USA. ashley.fortress@nih.gov.
Kiyoharu J MiyagishimaRetinal Neurophysiology Section, National Eye Institute, NIH, Bethesda, MD, USA.
Amberlynn A ReedNational Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Sally TempleNeural Stem Cell Institute, Rensselaer, NY, USA.
Dennis O CleggCenter for Stem Cell Biology and Engineering, University of California, Santa Barbara, CA, USA.
Budd A TuckerInstitute for Vision Research, Department of Ophthalmology and Visual Science, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Timothy A BlenkinsopOphthalmology Cell Development and Regenerative Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
George HarbCellino Biotech, Cambridge, MA, USA.
Thomas N GreenwellNational Eye Institute, National Institutes of Health, Bethesda, MD, USA. thomas.greenwell@nih.gov.
Tenneille E LudwigWiCell Research Institute, Madison, WI, USA.
Kapil BhartiOcular and Stem Cell Translational Research, National Eye Institute, NIH, Bethesda, MD, USA. kapil.bharti@nih.gov.ORCID 0000-0003-4884-3173
National Institutes of Health · USNational Eye Institute · USIcahn School of Medicine at Mount Sinai · USNeural Stem Cell Institute · USUniversity of California, Santa Barbara · USUniversity of Iowa · USWiCell · US

Funding

Reversing Contractility in Epiretinal MembranesR01EY029736 · NEI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BLENKINSOP, TIMOTHY A. · 2020 to 2024
$2.0M
NEI NIH HHS R01 EY029736
6 · The paper itself

Abstract

National Eye Institute recently issued a new Strategic Plan outlining priority research areas for the next 5 years. Starting cell source for deriving stem cell lines is as an area with gaps and opportunities for making progress in regenerative medicine, a key area of emphasis within the NEI Strategic Plan. There is a critical need to understand how starting cell source affects the cell therapy product and what specific manufacturing capabilities and quality control standards are required for autologous vs allogeneic stem cell sources. With the goal of addressing some of these questions, in discussion with the community-at-large, NEI hosted a Town Hall at the Association for Research in Vision and Ophthalmology annual meeting in May 2022. This session leveraged recent clinical advances in autologous and allogeneic RPE replacement strategies to develop guidance for upcoming cell therapies for photoreceptors, retinal ganglion cells, and other ocular cell types. Our focus on stem cell-based therapies for RPE underscores the relatively advanced stage of RPE cell therapies to patients with several ongoing clinical trials. Thus, this workshop encouraged lessons learned from the RPE field to help accelerate progress in developing stem cell-based therapies in other ocular tissues. This report provides a synthesis of the key points discussed at the Town Hall and highlights needs and opportunities in ocular regenerative medicine.

Indexed as

Induced Pluripotent Stem CellsPluripotent Stem CellsRetinal DiseasesCell- and Tissue-Based TherapyHumansRetinal Pigment EpitheliumStem Cell TransplantationAllogeneicAutologousCell characterizationCell replacement therapyCell sourcesClinical manufacturingEmbryonic stem cellsInduced pluripotent stem cellsRetinal degenerationTranslational research

Identifiers

PMID36978104
PMCPMC10053463
OpenAlexW4361224217

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.